Siga Technologies Inc., a company that focuses on the creation and sale of solutions for biodefense and medical needs with unmet problems, recently launched its phase-one single ascending dose clinical study for TPOXX in an intravenous (IV) formulation.
TPOXX is the top drug candidate at the company. It is designed to treat orthopoxvirus diseases. To conduct the study, Siga collaborated with the Biomedical Research and Development Authority (BARDA).
Continue reading “Siga launches clinical study for TPOXX IV formulation”